Arbutus Biopharma (ABUS) Share-based Compensation (2012 - 2026)

Arbutus Biopharma (ABUS) has reported Share-based Compensation for 15 consecutive years, with $1.4 million the latest figure, recorded in Q1 2026.

• Quarterly Share-based Compensation fell 61.87% year-over-year to $1.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.7 million (down 54.94% YoY) and the FY2025 annual result came in at $7.0 million, down 22.62% from the prior year.
• Share-based Compensation rose to $1.4 million in Q1 2026 per ABUS's latest filing, from $1.3 million in the prior quarter.
• Over the last five years, Share-based Compensation for ABUS reached as high as $3.6 million in Q1 2025 and fell as low as $864000.0 in Q2 2025.
• A 5-year average of $2.0 million and a median of $1.7 million in 2022 frame the typical range for Share-based Compensation.
• The largest YoY upside for Share-based Compensation was 76.96% in 2025 against a maximum downside of 72.83% in 2025.
• Year by year, Share-based Compensation stood at $1.7 million in 2022, then grew by 3.36% to $1.7 million in 2023, then declined by 5.28% to $1.6 million in 2024, then retreated by 22.67% to $1.3 million in 2025, then gained by 7.69% to $1.4 million in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $1.4 million, $1.3 million, and $1.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.